The problem is that we're conflating what the PMPRB does currently with what's proposed.
Currently we compare our prices to PMPRB7, which is a fairly premium-priced set of countries.
What we're proposing is to compare ourselves to this basket of 12 countries where, on average, prices are more aligned or in tune with the OECD median. In the future, if these amendments come to pass, our list prices should converge toward the OECD median.
However, today, if you're a breakthrough drug or substantial improvement drug, you start off at the median of the PMPRB7, and then you're allowed to increase price in keeping with CPI until you hit that absolute ceiling of the highest international price. Typically, that's the U.S., where prices are two times to two and a half times higher than everybody else.
We start off at a ceiling that's not that stringent, and then it creeps up, it drifts up, toward the U.S., as opposed to going down towards the European countries that we compare ourselves to.